FDA Expands Evolocumab Label for Adults With Increased MACE Risk From Uncontrolled LDL-C
Evolocumab is now indicated for adults who don’t have a prior cardiovascular disease diagnosis.
Previous Post
Gene-edited pig lung transplanted into a brain-dead patient for first time
Next Post
Applied Behavior Analysis (ABA) Parent Training: Empowering You to Support Your Child for Success
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago